Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Fig. 2

Efficacy outcomes. Mean changes form baseline for A MHD, B MIDAS and C MAM at 6 and 12 months of follow-up. Blue lines indicate Anti-CGRP mAbs; red lines indicate BoNT-A; error bars represent 95%CI. Reported p-values are those from the unadjusted analysis. Abbreviations: MAM = migraine acute medications; MHD = monthly headache days; MIDAS = migraine disability assessment test

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us